| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 23 | 2022 | 335 | 5.860 |
Why?
|
| Arteriovenous Shunt, Surgical | 12 | 2019 | 71 | 3.960 |
Why?
|
| Kidney Failure, Chronic | 14 | 2022 | 413 | 3.890 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 219 | 2.080 |
Why?
|
| Kidney Transplantation | 5 | 2022 | 849 | 1.690 |
Why?
|
| Central Venous Catheters | 3 | 2016 | 22 | 1.590 |
Why?
|
| Catheterization, Peripheral | 4 | 2017 | 60 | 1.570 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2022 | 141 | 1.440 |
Why?
|
| Neuromuscular Junction | 3 | 2015 | 81 | 1.090 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2019 | 226 | 1.090 |
Why?
|
| Drosophila | 5 | 2015 | 521 | 1.010 |
Why?
|
| Catheterization, Central Venous | 2 | 2017 | 115 | 0.990 |
Why?
|
| Graft Rejection | 2 | 2021 | 1064 | 0.950 |
Why?
|
| Peritoneal Dialysis | 2 | 2020 | 31 | 0.840 |
Why?
|
| Drosophila Proteins | 7 | 2015 | 508 | 0.830 |
Why?
|
| Immunosuppressive Agents | 3 | 2019 | 975 | 0.830 |
Why?
|
| Cystatin C | 1 | 2022 | 28 | 0.830 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2021 | 20 | 0.800 |
Why?
|
| Graft Survival | 3 | 2021 | 898 | 0.720 |
Why?
|
| Biological Variation, Individual | 1 | 2019 | 7 | 0.690 |
Why?
|
| Aged | 22 | 2022 | 19077 | 0.690 |
Why?
|
| Transplant Recipients | 1 | 2021 | 137 | 0.690 |
Why?
|
| Presynaptic Terminals | 2 | 2015 | 41 | 0.690 |
Why?
|
| Transitional Care | 1 | 2019 | 18 | 0.680 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 34 | 0.660 |
Why?
|
| Middle Aged | 26 | 2022 | 25863 | 0.650 |
Why?
|
| Drug Monitoring | 1 | 2019 | 119 | 0.640 |
Why?
|
| Male | 32 | 2022 | 42251 | 0.640 |
Why?
|
| Tacrolimus | 2 | 2019 | 369 | 0.640 |
Why?
|
| Female | 32 | 2022 | 46011 | 0.630 |
Why?
|
| Patient Transfer | 1 | 2019 | 94 | 0.620 |
Why?
|
| Inpatients | 2 | 2015 | 310 | 0.620 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2009 | 99 | 0.610 |
Why?
|
| Body Mass Index | 1 | 2021 | 771 | 0.590 |
Why?
|
| Hemodialysis Solutions | 1 | 2017 | 2 | 0.580 |
Why?
|
| Treatment Outcome | 13 | 2021 | 8203 | 0.560 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 410 | 0.550 |
Why?
|
| Vascular Grafting | 1 | 2016 | 16 | 0.550 |
Why?
|
| Upper Extremity | 2 | 2015 | 52 | 0.540 |
Why?
|
| Mycophenolic Acid | 2 | 2013 | 84 | 0.510 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 2 | 2013 | 4 | 0.500 |
Why?
|
| Humans | 43 | 2022 | 89063 | 0.500 |
Why?
|
| Pulmonary Embolism | 2 | 2009 | 228 | 0.490 |
Why?
|
| Obesity | 1 | 2021 | 966 | 0.470 |
Why?
|
| Plasmapheresis | 1 | 2013 | 25 | 0.450 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 705 | 0.440 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 424 | 0.430 |
Why?
|
| Catheters, Indwelling | 3 | 2008 | 113 | 0.430 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 479 | 0.420 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 738 | 0.420 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 6777 | 0.390 |
Why?
|
| Hospitals, Urban | 2 | 2015 | 60 | 0.380 |
Why?
|
| Adult | 17 | 2022 | 26507 | 0.380 |
Why?
|
| United States | 6 | 2022 | 6955 | 0.380 |
Why?
|
| Neuronal Plasticity | 1 | 2013 | 193 | 0.370 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 105 | 0.350 |
Why?
|
| Retrospective Studies | 9 | 2022 | 9003 | 0.340 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 599 | 0.340 |
Why?
|
| Immunoglobulins | 2 | 2015 | 144 | 0.340 |
Why?
|
| Acute Kidney Injury | 4 | 2008 | 311 | 0.330 |
Why?
|
| Hypertension | 2 | 2020 | 741 | 0.320 |
Why?
|
| Synapses | 2 | 2015 | 278 | 0.320 |
Why?
|
| Spironolactone | 2 | 2009 | 12 | 0.310 |
Why?
|
| Fumarates | 1 | 2008 | 19 | 0.310 |
Why?
|
| Amides | 1 | 2008 | 53 | 0.310 |
Why?
|
| Lower Extremity | 1 | 2009 | 87 | 0.310 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 98 | 0.310 |
Why?
|
| Thromboembolism | 1 | 2009 | 120 | 0.300 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3657 | 0.290 |
Why?
|
| Thrombectomy | 1 | 2009 | 172 | 0.290 |
Why?
|
| Anticoagulants | 3 | 2009 | 426 | 0.280 |
Why?
|
| Paracentesis | 1 | 2006 | 10 | 0.280 |
Why?
|
| Embolism, Cholesterol | 1 | 2006 | 2 | 0.280 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2008 | 168 | 0.280 |
Why?
|
| Odds Ratio | 2 | 2020 | 684 | 0.270 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2006 | 4 | 0.270 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 214 | 0.270 |
Why?
|
| Ulnar Artery | 1 | 2006 | 5 | 0.270 |
Why?
|
| Risk Assessment | 3 | 2019 | 2290 | 0.270 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 249 | 0.260 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 250 | 0.260 |
Why?
|
| Collateral Circulation | 1 | 2006 | 35 | 0.260 |
Why?
|
| Risk Factors | 4 | 2019 | 5466 | 0.260 |
Why?
|
| Creatinine | 2 | 2022 | 293 | 0.260 |
Why?
|
| Aortic Diseases | 1 | 2006 | 100 | 0.260 |
Why?
|
| Thrombosis | 1 | 2008 | 302 | 0.250 |
Why?
|
| Protein Interaction Maps | 2 | 2015 | 49 | 0.250 |
Why?
|
| Pennsylvania | 3 | 2015 | 94 | 0.250 |
Why?
|
| Time Factors | 4 | 2019 | 5320 | 0.250 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 109 | 0.250 |
Why?
|
| Vascular Patency | 2 | 2019 | 126 | 0.240 |
Why?
|
| Heparin | 1 | 2005 | 185 | 0.240 |
Why?
|
| Hemorrhage | 2 | 2008 | 278 | 0.240 |
Why?
|
| Ascites | 1 | 2004 | 56 | 0.240 |
Why?
|
| Neoplasms | 1 | 2020 | 3035 | 0.240 |
Why?
|
| Databases, Factual | 2 | 2019 | 850 | 0.240 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2003 | 17 | 0.230 |
Why?
|
| Hyperkalemia | 1 | 2003 | 13 | 0.230 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2015 | 127 | 0.220 |
Why?
|
| Fibronectins | 1 | 2013 | 101 | 0.210 |
Why?
|
| Potassium Channels | 1 | 2005 | 343 | 0.210 |
Why?
|
| Patient Selection | 2 | 2008 | 682 | 0.210 |
Why?
|
| Equipment Design | 3 | 2015 | 415 | 0.200 |
Why?
|
| Cohort Studies | 2 | 2021 | 2863 | 0.200 |
Why?
|
| Outpatients | 1 | 2022 | 100 | 0.200 |
Why?
|
| Vitamin D Deficiency | 1 | 2022 | 103 | 0.190 |
Why?
|
| Receptors, Cell Surface | 3 | 2013 | 289 | 0.190 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 275 | 0.190 |
Why?
|
| Semaphorins | 1 | 2010 | 17 | 0.190 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2010 | 23 | 0.180 |
Why?
|
| Potassium | 2 | 2017 | 253 | 0.180 |
Why?
|
| Larva | 3 | 2015 | 121 | 0.180 |
Why?
|
| Calcium | 3 | 2022 | 1172 | 0.170 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2020 | 61 | 0.170 |
Why?
|
| Datasets as Topic | 1 | 2019 | 75 | 0.170 |
Why?
|
| Angioplasty | 1 | 2019 | 70 | 0.170 |
Why?
|
| Arteriovenous Fistula | 1 | 2019 | 53 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2006 | 2275 | 0.160 |
Why?
|
| Prevalence | 2 | 2020 | 1240 | 0.160 |
Why?
|
| Drosophila melanogaster | 1 | 2013 | 613 | 0.160 |
Why?
|
| Polymyositis | 1 | 2018 | 6 | 0.150 |
Why?
|
| Dermatomyositis | 1 | 2018 | 18 | 0.150 |
Why?
|
| Proteins | 1 | 2013 | 786 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 3443 | 0.150 |
Why?
|
| Lung Diseases | 1 | 2020 | 269 | 0.150 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2009 | 70 | 0.150 |
Why?
|
| Bicarbonates | 1 | 2017 | 58 | 0.140 |
Why?
|
| Appendicitis | 1 | 2017 | 64 | 0.140 |
Why?
|
| Autoantibodies | 1 | 2018 | 268 | 0.140 |
Why?
|
| Animals | 9 | 2015 | 27317 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2020 | 948 | 0.140 |
Why?
|
| Magnesium | 1 | 2017 | 178 | 0.140 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 360 | 0.130 |
Why?
|
| Renin | 2 | 2008 | 67 | 0.130 |
Why?
|
| Comorbidity | 1 | 2020 | 948 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2013 | 661 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2017 | 157 | 0.130 |
Why?
|
| Sodium | 1 | 2017 | 331 | 0.130 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2015 | 17 | 0.130 |
Why?
|
| Biomarkers | 1 | 2022 | 1755 | 0.130 |
Why?
|
| Second Messenger Systems | 1 | 2015 | 41 | 0.130 |
Why?
|
| Catheterization | 2 | 2007 | 237 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 266 | 0.130 |
Why?
|
| Acyltransferases | 1 | 2015 | 41 | 0.130 |
Why?
|
| Vesicular Transport Proteins | 1 | 2015 | 63 | 0.130 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2015 | 88 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 257 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 848 | 0.120 |
Why?
|
| Hospitals, Teaching | 1 | 2015 | 118 | 0.120 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2018 | 260 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2015 | 280 | 0.120 |
Why?
|
| Schizophrenia | 1 | 2017 | 479 | 0.110 |
Why?
|
| Blood Flow Velocity | 2 | 2019 | 198 | 0.110 |
Why?
|
| Protein Transport | 1 | 2015 | 421 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 1043 | 0.110 |
Why?
|
| HTLV-I Infections | 1 | 2013 | 7 | 0.110 |
Why?
|
| Strongyloidiasis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Meningitis, Bacterial | 1 | 2013 | 13 | 0.110 |
Why?
|
| Sex Factors | 1 | 2017 | 1063 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 146 | 0.110 |
Why?
|
| Organs at Risk | 1 | 2013 | 40 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2015 | 306 | 0.110 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2013 | 6 | 0.110 |
Why?
|
| Medicare | 1 | 2017 | 423 | 0.110 |
Why?
|
| Logistic Models | 1 | 2017 | 1212 | 0.110 |
Why?
|
| Vitiligo | 1 | 2013 | 17 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2015 | 229 | 0.110 |
Why?
|
| Fertility Preservation | 1 | 2013 | 22 | 0.110 |
Why?
|
| Graves Disease | 1 | 2013 | 36 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1940 | 0.110 |
Why?
|
| Animals, Genetically Modified | 2 | 2010 | 183 | 0.100 |
Why?
|
| Prognosis | 2 | 2018 | 3773 | 0.100 |
Why?
|
| Survival Rate | 1 | 2016 | 1889 | 0.100 |
Why?
|
| Medical Tourism | 1 | 2011 | 5 | 0.100 |
Why?
|
| Hand | 1 | 2013 | 133 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 266 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2013 | 3373 | 0.100 |
Why?
|
| Leishmania | 1 | 2001 | 7 | 0.100 |
Why?
|
| Protein Binding | 1 | 2015 | 1487 | 0.100 |
Why?
|
| Cadaver | 1 | 2011 | 185 | 0.100 |
Why?
|
| Cyclosporine | 2 | 2007 | 237 | 0.090 |
Why?
|
| RNA Editing | 1 | 2001 | 35 | 0.090 |
Why?
|
| Stroke | 1 | 2020 | 982 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2011 | 229 | 0.090 |
Why?
|
| Adolescent | 3 | 2018 | 9237 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1706 | 0.080 |
Why?
|
| Sequence Alignment | 2 | 2015 | 353 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1215 | 0.080 |
Why?
|
| Brachial Artery | 1 | 2009 | 36 | 0.080 |
Why?
|
| Equipment Contamination | 1 | 2008 | 23 | 0.080 |
Why?
|
| Veins | 1 | 2009 | 95 | 0.080 |
Why?
|
| Tomography, Spiral Computed | 1 | 2009 | 77 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2011 | 490 | 0.080 |
Why?
|
| Biofilms | 1 | 2008 | 46 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 105 | 0.080 |
Why?
|
| Biological Availability | 1 | 2008 | 92 | 0.080 |
Why?
|
| Prednisolone | 1 | 2007 | 40 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2007 | 171 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 345 | 0.070 |
Why?
|
| Neurons | 1 | 2015 | 1580 | 0.070 |
Why?
|
| Equipment Safety | 1 | 2006 | 33 | 0.070 |
Why?
|
| Women's Health | 1 | 2007 | 102 | 0.070 |
Why?
|
| Hemoptysis | 1 | 2006 | 24 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2008 | 682 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2019 | 4273 | 0.070 |
Why?
|
| Shock | 1 | 2006 | 44 | 0.070 |
Why?
|
| Amino Acid Sequence | 2 | 2015 | 2062 | 0.070 |
Why?
|
| Albumins | 1 | 2006 | 129 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 783 | 0.070 |
Why?
|
| Demography | 1 | 2006 | 181 | 0.070 |
Why?
|
| Radial Artery | 1 | 2006 | 33 | 0.070 |
Why?
|
| Stomach | 1 | 2006 | 111 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 299 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2005 | 23 | 0.060 |
Why?
|
| Kidney | 2 | 2006 | 1145 | 0.060 |
Why?
|
| Organizational Culture | 1 | 2005 | 32 | 0.060 |
Why?
|
| Critical Care | 1 | 2008 | 380 | 0.060 |
Why?
|
| Personnel, Hospital | 1 | 2005 | 30 | 0.060 |
Why?
|
| Spleen | 1 | 2006 | 432 | 0.060 |
Why?
|
| Japan | 2 | 2017 | 303 | 0.060 |
Why?
|
| Kidney Calculi | 1 | 2008 | 341 | 0.060 |
Why?
|
| Shaker Superfamily of Potassium Channels | 1 | 2005 | 49 | 0.060 |
Why?
|
| Nephrology | 1 | 2005 | 41 | 0.060 |
Why?
|
| Platelet Count | 1 | 2004 | 93 | 0.060 |
Why?
|
| Respiratory Insufficiency | 1 | 2006 | 162 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2004 | 127 | 0.060 |
Why?
|
| Acute Disease | 1 | 2006 | 841 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 833 | 0.060 |
Why?
|
| Radiography | 1 | 2006 | 809 | 0.060 |
Why?
|
| Aldosterone | 1 | 2003 | 56 | 0.060 |
Why?
|
| Nephrectomy | 1 | 2005 | 293 | 0.060 |
Why?
|
| Endocarditis | 1 | 2003 | 21 | 0.050 |
Why?
|
| Brain | 1 | 2013 | 2281 | 0.050 |
Why?
|
| Ligands | 1 | 2013 | 443 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 83 | 0.050 |
Why?
|
| Behavior, Animal | 1 | 2005 | 378 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 740 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 216 | 0.050 |
Why?
|
| Liver | 1 | 2006 | 1205 | 0.050 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2010 | 30 | 0.050 |
Why?
|
| Calcium Channels, N-Type | 1 | 2010 | 17 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2004 | 899 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2002 | 170 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 531 | 0.040 |
Why?
|
| Muscles | 1 | 2010 | 193 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 268 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 643 | 0.040 |
Why?
|
| Lung | 1 | 2006 | 1258 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2010 | 354 | 0.040 |
Why?
|
| Embryo, Nonmammalian | 1 | 2010 | 196 | 0.040 |
Why?
|
| Kidneys, Artificial | 1 | 2019 | 4 | 0.040 |
Why?
|
| Motor Neurons | 1 | 2010 | 174 | 0.040 |
Why?
|
| Brachiocephalic Veins | 1 | 2019 | 34 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2019 | 85 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 3027 | 0.040 |
Why?
|
| Phenotype | 1 | 2005 | 2439 | 0.040 |
Why?
|
| Aspirin | 1 | 2019 | 159 | 0.040 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2018 | 10 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2002 | 395 | 0.040 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2018 | 14 | 0.040 |
Why?
|
| Somatosensory Disorders | 1 | 2017 | 3 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2018 | 130 | 0.040 |
Why?
|
| Phylogeny | 1 | 2013 | 1182 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 511 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 242 | 0.040 |
Why?
|
| Action Potentials | 1 | 2010 | 596 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2010 | 537 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 6288 | 0.030 |
Why?
|
| Multigene Family | 1 | 2015 | 203 | 0.030 |
Why?
|
| Streptococcus bovis | 1 | 2013 | 2 | 0.030 |
Why?
|
| Coinfection | 1 | 2013 | 61 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1855 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1867 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 221 | 0.030 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 1991 | 8 | 0.030 |
Why?
|
| RNA, Protozoan | 1 | 2001 | 5 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1296 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 1991 | 92 | 0.020 |
Why?
|
| Uridine | 1 | 2001 | 56 | 0.020 |
Why?
|
| Protozoan Proteins | 1 | 2001 | 73 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2001 | 342 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2001 | 232 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2001 | 509 | 0.020 |
Why?
|
| Dialysis Solutions | 1 | 2008 | 7 | 0.020 |
Why?
|
| Mutation | 1 | 2010 | 4132 | 0.020 |
Why?
|
| Convection | 1 | 2008 | 12 | 0.020 |
Why?
|
| Hypothermia | 1 | 2008 | 26 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2008 | 120 | 0.020 |
Why?
|
| Diffusion | 1 | 2008 | 93 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2001 | 2011 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2008 | 121 | 0.020 |
Why?
|
| Mitochondria | 1 | 2001 | 553 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1991 | 1157 | 0.020 |
Why?
|
| RNA | 1 | 2001 | 578 | 0.020 |
Why?
|
| Critical Illness | 1 | 2008 | 306 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2008 | 729 | 0.020 |
Why?
|
| Sepsis | 1 | 2008 | 319 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 312 | 0.010 |
Why?
|
| Gene Expression | 1 | 1991 | 1310 | 0.000 |
Why?
|
| Rats | 1 | 1991 | 4040 | 0.000 |
Why?
|
| Models, Biological | 1 | 1991 | 1763 | 0.000 |
Why?
|